<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03815903</url>
  </required_header>
  <id_info>
    <org_study_id>BarretoCH - 201801</org_study_id>
    <nct_id>NCT03815903</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma</brief_title>
  <acronym>INDUCTION</acronym>
  <official_title>A Phase 3, Randomized, Open-label Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barretos Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barretos Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The benefit of induction chemotherapy followed by chemoradiotherapy for locally advanced head&#xD;
      and neck squamous cell carcinoma is unknown. The present study is investigating if this&#xD;
      therapeutic strategy improve overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-years overall survival</measure>
    <time_frame>From date of randomization until 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic relapse free survival</measure>
    <time_frame>From date of randomization until the date of first systemic relapse or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>At the end of Cycle 3 of IC (each cycle is 21 days) and 8 weeks after the end of radiotherapy, through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Rates</measure>
    <time_frame>At the end of cycle 1, cycle 2 and cycle 3 (each cycle is 21 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year functional organ preservation rate</measure>
    <time_frame>From date of randomization until 1 year after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EORTC Quality of Life Questionnare - C30 version 3.0)</measure>
    <time_frame>From date of randomization until 5 years</time_frame>
    <description>The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate to induction chemotherapy</measure>
    <time_frame>At the end of Cycle 3 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">434</enrollment>
  <condition>Locally Advanced Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>A - induction chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B - chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction chemotherapy</intervention_name>
    <description>3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2</description>
    <arm_group_label>A - induction chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Chemoradiotherapy</intervention_name>
    <description>Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2</description>
    <arm_group_label>A - induction chemotherapy</arm_group_label>
    <arm_group_label>B - chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed histological diagnosis of squamous cell carcinoma or undifferentiated&#xD;
             carcinoma of the oropharynx, hypopharynx or larynx;&#xD;
&#xD;
          -  Locally advanced stage (stage IVa / b - AJCC 8th edition), classified as resectable **&#xD;
             or unresectable and candidate for treatment based on radiotherapy and chemotherapy;&#xD;
&#xD;
          -  Locally advanced stage (stage III - AJCC 8th edition), classified as resectable or&#xD;
             unresectable, positive p16 and candidate for treatment based on radiotherapy and&#xD;
             chemotherapy;&#xD;
&#xD;
          -  It will be allowed to include a patient with cervical lymphadenectomy if the primary&#xD;
             lesion is measurable;&#xD;
&#xD;
          -  Presence of measurable disease according to RECIST 1.1 criteria;&#xD;
&#xD;
          -  ECOG performance status of 0-1;&#xD;
&#xD;
          -  ≥ 18 years;&#xD;
&#xD;
          -  Adequate marrow reserve indicated by:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500 / mm³ or Platelets&gt; 100,000 / mm³&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g / dL - red blood cell transfusion will be allowed in the&#xD;
                  screening period if necessary&#xD;
&#xD;
          -  Adequate renal and hepatic function:&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 times the upper limit of normal the TGO and TGP ≤ 3 upper&#xD;
                  limit of normal. If hepatic metastasis ≤ 5 upper limit of normal&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 mg / dL and creatinine clearance ≥ 60 mL / min calculated&#xD;
                  by Cockcroft-Gault.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient submitted to curative resection of the primary site and / or metastatic site.&#xD;
             NOTE: Patients submitted to cervical lymphadenectomy without surgery to the primary&#xD;
             tumor are eligible;&#xD;
&#xD;
          -  Radiation therapy or previous chemotherapy for head / neck tumor;&#xD;
&#xD;
          -  Patients with occult primary tumor;&#xD;
&#xD;
          -  T4 from any site, resectable, with invasion of cartilage or jaw;&#xD;
&#xD;
          -  History of BMT or stem cell therapy;&#xD;
&#xD;
          -  Synchronous tumor or previous history of neoplasia, except for in situ carcinoma of&#xD;
             the cervix, basal cell carcinoma or epidermoid carcinoma. Patients with previous&#xD;
             history of cancer already treated and without evidence of disease for more than 3&#xD;
             years may participate in the study;&#xD;
&#xD;
          -  Prophylactic use of G-CSF or GM-CSF two weeks prior to the study;&#xD;
&#xD;
          -  Clinically significant heart disease: unstable angina or myocardial infarction 6&#xD;
             months prior to study entry Symptomatic ventricular arrhythmia the ICC classified as&#xD;
             NYHA ≥ II • Uncontrolled hypercalcemia;&#xD;
&#xD;
          -  Uncontrolled infection;&#xD;
&#xD;
          -  Any other comorbidity that the investigator's judgment is inappropriate for the study;&#xD;
&#xD;
          -  Peripheral neuropathy&gt; grade 2;&#xD;
&#xD;
          -  Hearing loss&gt; grade 2;&#xD;
&#xD;
          -  Known positive serology for hepatitis B, hepatitis C or HIV&#xD;
&#xD;
          -  Use of antiretrovirals;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro De Marchi, MD, MSc</last_name>
      <phone>+55 17 33216600</phone>
      <phone_ext>6953</phone_ext>
      <email>pedrodemarchi@yahoo.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Raiany Carvalho, RN</last_name>
      <phone>+55 17 33216600</phone>
      <phone_ext>6712</phone_ext>
      <email>raiany.carvalho@hcancerbarretos.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Augusto E Mamere, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre A Jacinto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Domingos Boldrini Junior, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renato C Capuzzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos R Santos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre L Carvalho, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luciano S Vianna, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josiane D Mourão, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo R Gama, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gustavo J Dix, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diogo D Prado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro De Marchi, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

